Affordable Access

Access to the full text

Outcome of children with oligoarticular juvenile idiopathic arthritis compared to polyarthritis on methotrexate- data of the German BIKER registry

  • Raab, A.1
  • Kallinich, T.1
  • Huscher, D.2
  • Foeldvari, I.3
  • Weller-Heinemann, F.4, 5
  • Dressler, F.6
  • Kuemmerle-Deschner, J. B.7
  • Klein, A.8
  • Horneff, G.8
  • 1 Children’s university hospital Charité, Augustenburger Platz 1, Berlin, 13353, Germany , Berlin (Germany)
  • 2 Institute of Biometry and Clinical Epidemiology and Berlin Institute of Health, Charité – Universitätsmedizin, Berlin, Germany , Berlin (Germany)
  • 3 Hamburg Centre for Pediatric and Adolescence Rheumatology Centre for Treatment of Scleroderma and Uveitis in Childhood and Adolescence, Hamburg, Germany , Hamburg (Germany)
  • 4 Prof. Hess Children’s Hospital, Bremen, Germany , Bremen (Germany)
  • 5 University Hospital of Cologne, Cologne, Germany , Cologne (Germany)
  • 6 Hannover Medical School, Hannover, Germany , Hannover (Germany)
  • 7 University Hospital Tuebingen, Tuebingen, Germany , Tuebingen (Germany)
  • 8 Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany , Sankt Augustin (Germany)
Published Article
Pediatric Rheumatology
Springer Science and Business Media LLC
Publication Date
Mar 22, 2021
DOI: 10.1186/s12969-021-00522-4
Springer Nature


BackgroundOligoarticular juvenile idiopathic arthritis (oligoJIA) is the most commonly diagnosed category of chronic arthritis in children. Nevertheless, there are no evidence- based guidelines for its treatment, in particular for the use of methotrexate (MTX). The primary objective of this analysis is to evaluate the outcomes in patients with persistent oligoJIA compared to those with extended oligoJIA and rheumatoid factor (RF) negative polyarthritis treated with methotrexate.MethodsPatients with persistent or extended oligoJIA or RF negative PA recorded in the Biologics in Pediatric Rheumatology Registry (BiKeR), receiving methotrexate for the first time were included in the analyses. Efficacy was determined using the Juvenile Arthritis Disease Activity Score 10 (JADAS 10). Safety assessment included the documentation of adverse and serious adverse events.ResultsFrom 2005 through 2011, 1056 patients were included: 370 patients with persistent oligoJIA, 221 patients with extended oligoJIA and 467 patients with RF negative PA. Therapeutic efficacy was observed following the start of methotrexate.Over a period of 24 months JADAS-minimal disease activity (JADAS ≤2) was reached in 44% of patients with persistent oligoJIA, 38% with extended oligoJIA, 46% with RF negative PA, JADAS-remission defined as JADAS ≤1 was reached in 33% of patients with persistent oligoJIA, 29% with extended oligoJIA and 35% (RF negative PA). Patients with extended oligoJIA achieved JADAS remission significantly later and received additional biologic disease-modifying drugs significantly more often than patients with persistent oligoJIA or RF negative PA (p < 0.001). Tolerability was comparable. New onset uveitis occurred in 0.3 to 2.2 per 100 patient years.ConclusionsPatients with persistent oligoJIA taking methotrexate are at least as likely to enter remission as patients with extended oligo JIA or polyarticular JIA. Patients with extended oligoJIA achieved JADAS remission significantly later. Within 2 years, almost half of the patients with persistent oligoJIA achieved JADAS-minimal disease activity.

Report this publication


Seen <100 times